Taken together, all these data demonstrated that co-expression of n- ERβ1 and c-ERβ conferred the resistance of NSCLC to EGFR-TKI treatment, which was due to the interactions between ERβ1 and ERβ2 or ERβ1 and ERβ5. This evidence concerns the gene EGFR and non-small cell lung carcinoma.